Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension
- PMID: 18235092
- PMCID: PMC2390968
- DOI: 10.1681/ASN.2007060713
Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension
Abstract
Cytochrome P450 4F2 (CYP4F2) catalyzes the omega-hydroxylation of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a natriuretic and vasoactive eicosanoid that participates in the development of hypertension. The relationship among CYP4F2 genetic variants in the regulatory region, formation of renal 20-HETE, and hypertension is unknown. Here are reported seven genetic variants around the CYP4F2 intronic regulatory region. Four of these variants made up two common haplotypes, Hap I (c.-91T/c.-48G/c.-13T/c.+34T) and Hap II (c.-91C/c.-48C/c.-13C/c.+34G). Hap I included a major functional variant, c.-91T-->C, which was identified by reporter assay and electrophoretic mobility shift assay. Transfected into HEK293 cells, the Hap I construct showed a trend toward higher basal transcriptional activity and exhibited significantly greater LPS-stimulated activity than Hap II; these findings were the result of different NF-kappaB binding affinity between the two constructs. In vivo, a case-control study demonstrated that homozygosity for Hap I doubled the risk for hypertension in a Chinese population, even after adjustment for risk factors including age, gender, and body mass index. This association was confirmed in a family-based association study. In addition, Hap I was associated with elevated urinary 20-HETE. These results indicate that a functional variant of the CYP4F2 regulatory region, which increases the binding affinity of NF-kappaB, increases the risk for hypertension, likely by modulating the production of 20-HETE.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2390968/bin/asn0040835830001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2390968/bin/asn0040835830002.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2390968/bin/asn0040835830003.gif)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2390968/bin/asn0040835830004.gif)
Similar articles
-
The CYP/20-HETE/GPR75 axis in hypertension.Adv Pharmacol. 2022;94:1-25. doi: 10.1016/bs.apha.2022.02.003. Epub 2022 Mar 30. Adv Pharmacol. 2022. PMID: 35659370 Free PMC article. Review.
-
20-HETE and blood pressure regulation: clinical implications.Cardiol Rev. 2014 Jan-Feb;22(1):1-12. doi: 10.1097/CRD.0b013e3182961659. Cardiol Rev. 2014. PMID: 23584425 Free PMC article. Review.
-
Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure.Kidney Int. 2009 Jun;75(12):1288-1296. doi: 10.1038/ki.2009.67. Epub 2009 Mar 11. Kidney Int. 2009. PMID: 19279555
-
A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure.Hypertension. 2008 May;51(5):1393-8. doi: 10.1161/HYPERTENSIONAHA.107.104463. Epub 2008 Apr 7. Hypertension. 2008. PMID: 18391101
-
Functional polymorphism in human CYP4F2 decreases 20-HETE production.Physiol Genomics. 2007 Jun 19;30(1):74-81. doi: 10.1152/physiolgenomics.00003.2007. Epub 2007 Mar 6. Physiol Genomics. 2007. PMID: 17341693
Cited by
-
Bioactive lipids in hypertension.Adv Pharmacol. 2023;97:1-35. doi: 10.1016/bs.apha.2023.01.001. Epub 2023 May 10. Adv Pharmacol. 2023. PMID: 37236756 Free PMC article.
-
Urinary 20-HETE: A prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease.J Adv Res. 2023 Feb;44:109-117. doi: 10.1016/j.jare.2022.04.013. Epub 2022 Apr 28. J Adv Res. 2023. PMID: 36725183 Free PMC article.
-
Urinary Sediment Transcriptomic and Longitudinal Data to Investigate Renal Function Decline in Type 1 Diabetes.Front Endocrinol (Lausanne). 2020 Apr 30;11:238. doi: 10.3389/fendo.2020.00238. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32425885 Free PMC article.
-
20-HETE in the regulation of vascular and cardiac function.Pharmacol Ther. 2018 Dec;192:74-87. doi: 10.1016/j.pharmthera.2018.07.004. Epub 2018 Jul 23. Pharmacol Ther. 2018. PMID: 30048707 Free PMC article. Review.
-
Conflicting roles of 20-HETE in hypertension and renal end organ damage.Eur J Pharmacol. 2018 Aug 15;833:190-200. doi: 10.1016/j.ejphar.2018.06.010. Epub 2018 Jun 7. Eur J Pharmacol. 2018. PMID: 29886242 Free PMC article. Review.
References
-
- Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK: Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: Role of Cyp4F2 and Cyp4A11. J Biol Chem 275: 4118–4126, 2000 - PubMed
-
- Kikuta Y, Kusunose E, Kusunose M: Characterization of human liver leukotriene B4-hydroxylase P450 (CYP4F2). J Biochem 127: 1047–1052, 2000 - PubMed
-
- Sontag TJ, Parker RS: Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: Novel mechanism of regulation of vitamin E status. J Biol Chem 277: 25290–25296, 2002 - PubMed
-
- McGiff JC, Quilley J: 20-HETE and the kidney: Resolution of old problems and new beginnings. Am J Physiol 277: R607–R623, 1999 - PubMed
-
- Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131–185, 2002 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical